-
May 4, 2022 Interview With Daniel Carcillo, Natalie Ginsberg, Olivia Mannix & Klee IrwinThis week on the Psychedelic Spotlight podcast, we provide a recap of the inaugural Benzinga...
-
May 2, 2022 Elon Musk Excites Psychedelic Industry CEOs with This TweetThis is one of the billionaire's most explicit acknowledgments of the power of psychedelics for...
-
April 30, 2022 Kevin O’Leary Thinks MindMed, Compass Pathways & atai Will Merge | Is this a Good Idea?Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20...
-
April 29, 2022 Why Field Trip Health Is Dividing in Two — and What This Means for InvestorsField Trip Health plans to split into two independent, publicly traded companies: Field Trip Health...
-
April 29, 2022 Psychedelic Business Spotlight – April 29This week in psychedelic business news: Field Trip Health splits in two, Tryp Therapeutics commences...
-
April 22, 2022 Understanding 3 Risks of Investing in Psychedelic StocksNo one is responsible for your financial future, other than yourself, so be responsible with...
-
April 22, 2022 Psychedelic Business Spotlight – April 22This week in psychedelic business news: Mindset Pharma files a new patent; Ehave's MetaHealthU app...
-
April 21, 2022 Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?Our resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial...
-
April 15, 2022 Psychedelic Business Spotlight – April 15This week in psychedelic business news: The industry's first major merger; NeonMind launches clinics; a...
-
April 14, 2022 Why Investors Should Care About MindMed’s LSD Trial for AnxietyMindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with...
